A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer

CONCLUSIONS: Hemay022 at the dose of 500 mg once daily was well tolerated. The pharmacokinetic properties and encouraging anti-tumor activities of Hemay022 in advanced breast cancer patients warranted further evaluation of Hemay022 for treating breast cancer patients in the current phase III trial (No. NCT05122494).PMID:38455366 | PMC:PMC10915640 | DOI:10.21147/j.issn.1000-9604.2024.01.05
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research